CYP19A1 and neoplasm: Studies have found that for patients who retain their uterus and/or ovaries, as well as those with incomplete resection, adjuvant anti-estrogen therapy (such as tamoxifen, aromatase inhibitors, and gonadotropin-releasing hormone agonist GnRH-a) can prevent tumor recurrence or continued growth of residual lesions (25–27).